Sign in
Alogliptin for the treatment of type 2 diabetes
Journal article

Alogliptin for the treatment of type 2 diabetes

J R White
Drugs of today (Barcelona, Spain : 1998), Vol.47(2), pp.99-107
02/2011
Handle:
https://hdl.handle.net/2376/105903
PMID: 21431099

Abstract

Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Humans Drug Approval Drug Interactions Piperidines - pharmacokinetics Uracil - chemistry Hypoglycemic Agents - therapeutic use Hypoglycemic Agents - pharmacokinetics Piperidines - chemistry Uracil - therapeutic use Dipeptidyl-Peptidase IV Inhibitors - chemistry Treatment Outcome Hypoglycemic Agents - chemistry Evidence-Based Medicine Blood Glucose - drug effects Diabetes Mellitus, Type 2 - blood Uracil - adverse effects Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics Piperidines - therapeutic use Piperidines - adverse effects Diabetes Mellitus, Type 2 - drug therapy Uracil - pharmacokinetics Hypoglycemic Agents - adverse effects Uracil - analogs & derivatives

Metrics

6 Record Views

Details